{"nct_id":"NCT04634825","title":"Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer","status":"TERMINATED","status_verified_date":"2023-12","start_date":"2021-03-17","start_date_type":"ACTUAL","primary_completion_date":"2022-07-29","primary_completion_date_type":"ACTUAL","completion_date":"2022-07-29","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["MGNX"]}